5Steven H, Nancy LH, Stefano AP, et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues [M]. IARC press: Lyon, 2008: 358-360.
6Girschikofsky M, Arico M, Castillo D, et al. Management of adult patients with Langerhans cell histiocytosis: recommenda- tions fi'om an expert panel on behalf of Euro-Histio-Net [ J]. Orphanet J Rare Dis, 2013, 8: 72. doi: 10.1186/1750-1172-8-72.
7Haupt R, Minkov M, Astigarraga I, et al. Langerhans cell histio- cytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years[J]. Pediatr Blood Cancer, 2013, 60(2): 175-184 doi: 10.I002/pbc.24367.
8Gadner H, Minkov M, Grois N, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis [J]. Blood, 2013, 121 (25): 5006-5014. doi: 10.1182/blood- 2012-09-455774.
9Smith PJ, Sou6s S. Multilevel therapeutic targeting by topoisom- erase inhibitors[ J ]. Br J Cancer Suppl, 1994, 23:$47-51.
10Sormeveld P. Teniposide in lymphomas and leukemias [J]. Semin Oncol, 1992, 19(2 Suppl 6): 59-64.
